These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 25230579)
1. Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT. Doberstein K; Harter PN; Haberkorn U; Bretz NP; Arnold B; Carretero R; Moldenhauer G; Mittelbronn M; Altevogt P Int J Cancer; 2015 Mar; 136(5):E326-39. PubMed ID: 25230579 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma. Wolterink S; Moldenhauer G; Fogel M; Kiefel H; Pfeifer M; Lüttgau S; Gouveia R; Costa J; Endell J; Moebius U; Altevogt P Cancer Res; 2010 Mar; 70(6):2504-15. PubMed ID: 20215505 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of L1CAM is associated with tumor progression and prognosis via ERK signaling in gastric cancer. Ito T; Yamada S; Tanaka C; Ito S; Murai T; Kobayashi D; Fujii T; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Kodera Y Ann Surg Oncol; 2014 Feb; 21(2):560-8. PubMed ID: 24046108 [TBL] [Abstract][Full Text] [Related]
5. L1 cell adhesion molecule induces melanoma cell motility by activation of mitogen-activated protein kinase pathways. Yi YS; Baek KS; Cho JY Pharmazie; 2014 Jun; 69(6):461-7. PubMed ID: 24974583 [TBL] [Abstract][Full Text] [Related]
6. L1 cell adhesion molecule promotes tumorigenicity and metastatic potential in non-small cell lung cancer. Hai J; Zhu CQ; Bandarchi B; Wang YH; Navab R; Shepherd FA; Jurisica I; Tsao MS Clin Cancer Res; 2012 Apr; 18(7):1914-24. PubMed ID: 22307136 [TBL] [Abstract][Full Text] [Related]
7. Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM. Cho S; Park I; Kim H; Jeong MS; Lim M; Lee ES; Kim JH; Kim S; Hong HJ MAbs; 2016; 8(2):414-25. PubMed ID: 26785809 [TBL] [Abstract][Full Text] [Related]
8. Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Schäfer H; Dieckmann C; Korniienko O; Moldenhauer G; Kiefel H; Salnikov A; Krüger A; Altevogt P; Sebens S Cancer Lett; 2012 Jun; 319(1):66-82. PubMed ID: 22210381 [TBL] [Abstract][Full Text] [Related]
10. EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-κB activation. Kiefel H; Bondong S; Pfeifer M; Schirmer U; Erbe-Hoffmann N; Schäfer H; Sebens S; Altevogt P Carcinogenesis; 2012 Oct; 33(10):1919-29. PubMed ID: 22764136 [TBL] [Abstract][Full Text] [Related]
11. alpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma. Sebens Müerköster S; Kötteritzsch J; Geismann C; Gast D; Kruse ML; Altevogt P; Fölsch UR; Schäfer H Int J Oncol; 2009 Jan; 34(1):243-53. PubMed ID: 19082495 [TBL] [Abstract][Full Text] [Related]
12. Aberrant l1 cell adhesion molecule affects tumor behavior and chemosensitivity in anaplastic thyroid carcinoma. Kim KS; Min JK; Liang ZL; Lee K; Lee JU; Bae KH; Lee MH; Lee SE; Ryu MJ; Kim SJ; Kim YK; Choi MJ; Jo YS; Kim JM; Shong M Clin Cancer Res; 2012 Jun; 18(11):3071-8. PubMed ID: 22472175 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118 [TBL] [Abstract][Full Text] [Related]
14. Knockdown of L1CAM significantly reduces metastasis in a xenograft model of human melanoma: L1CAM is a potential target for anti-melanoma therapy. Ernst AK; Putscher A; Samatov TR; Suling A; Galatenko VV; Shkurnikov MY; Knyazev EN; Tonevitsky AG; Haalck T; Lange T; Maar H; Schröder-Schwarz J; Riecken K; Schumacher U; Wicklein D PLoS One; 2018; 13(2):e0192525. PubMed ID: 29432466 [TBL] [Abstract][Full Text] [Related]
15. Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model. Song IH; Jeong MS; Hong HJ; Shin JI; Park YS; Woo SK; Moon BS; Kim KI; Lee YJ; Kang JH; Lee TS Clin Cancer Res; 2019 Oct; 25(20):6148-6159. PubMed ID: 31337646 [TBL] [Abstract][Full Text] [Related]
17. L1CAM-integrin interaction induces constitutive NF-kappaB activation in pancreatic adenocarcinoma cells by enhancing IL-1beta expression. Kiefel H; Bondong S; Erbe-Hoffmann N; Hazin J; Riedle S; Wolf J; Pfeifer M; Arlt A; Schäfer H; Müerköster SS; Altevogt P Oncogene; 2010 Aug; 29(34):4766-78. PubMed ID: 20543863 [TBL] [Abstract][Full Text] [Related]
18. Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment. Lund K; Dembinski JL; Solberg N; Urbanucci A; Mills IG; Krauss S PLoS One; 2015; 10(4):e0123684. PubMed ID: 25860483 [TBL] [Abstract][Full Text] [Related]
19. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis. Knogler K; Grünberg J; Zimmermann K; Cohrs S; Honer M; Ametamey S; Altevogt P; Fogel M; Schubiger PA; Novak-Hofer I Clin Cancer Res; 2007 Jan; 13(2 Pt 1):603-11. PubMed ID: 17255283 [TBL] [Abstract][Full Text] [Related]
20. Activation of AKT signaling promotes epithelial-mesenchymal transition and tumor growth in colorectal cancer cells. Suman S; Kurisetty V; Das TP; Vadodkar A; Ramos G; Lakshmanaswamy R; Damodaran C Mol Carcinog; 2014 Feb; 53 Suppl 1():E151-60. PubMed ID: 24000138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]